Memphasys clears Vietnam regulatory hurdle as Felix moves into commercial rollout

Memphasys has ticked off a key commercial milestone in Vietnam, securing registration for its Felix System and triggering a 600-cartridge order from local distributor TMSC Vietnam.

For investors, the importance of the development is less about the headline regulatory approval and more about what comes next. Registration converts Vietnam from a market-entry exercise into an active commercial territory, with contracted cartridge purchases, clinic engagement and early clinical use now under way.

The company said registration was achieved in August 2026, matching the timetable previously communicated to the market. The clearance allows full commercial sales of Felix to begin and activates the first major purchase under Memphasys' two-year exclusive commercialisation agreement with TMSC Vietnam.

A 600-cartridge order puts some meat on the commercial bones

The initial commercial order covers 600 Felix cartridges and sits within a two-year agreement worth A$530,000.

That contract is structured across A$205,000 in the first year and A$325,000 in the second, with quarterly cartridge volumes expected to increase as clinic adoption develops.

Importantly, the new order is not starting from zero. Memphasys had already supplied 100 cartridges and three consoles for testing, product introduction and clinical preparation. Adding the latest order takes the total number of cartridges delivered or ordered for Vietnam to 700.

That progression matters. Medical-device companies can spend years talking about market access while investors wait for regulatory approvals, distributor appointments and actual purchase orders to line up. In Vietnam, those pieces are beginning to connect.

The 600-cartridge order also forms part of previously contracted purchase commitments, so investors should distinguish between fresh incremental contract value and the execution of an existing agreement. Still, moving from contract signing to product ordering and commercial supply reduces one layer of execution risk.

The distributor has spent the past several weeks introducing Felix to clinics, meaning the commercial rollout is moving beyond regulatory paperwork and into the harder task of generating repeat usage.

Vietnam could become a useful test of the recurring revenue model

Memphasys is positioning Felix as an alternative sperm-selection system for assisted reproduction, using electrophoresis and size-exclusion membranes rather than traditional centrifugation.

The company says the system is designed to provide a fast, gentle and standardised sperm-selection process while reducing laboratory time and avoiding some of the cellular stress associated with centrifugation.

For shareholders, the commercial model is particularly relevant. Felix combines reusable consoles with consumable cartridges, meaning meaningful adoption could generate recurring cartridge revenue rather than relying solely on one-off equipment sales.

Vietnam provides an early opportunity to test whether that recurring model can translate from agreements on paper into steady clinic usage.

TMSC Vietnam appears strategically suited to the job. The Hanoi-based distributor focuses on reproductive health, diagnostics, digital health tools and medical devices, and already has relationships across the local healthcare system. Memphasys will support product education, clinical positioning and selected clinic engagement while TMSC Vietnam handles local market development and distribution.

The next question is adoption, not approval

With registration complete, the investment story in Vietnam now changes.

Regulatory timing has been delivered. The first substantial commercial cartridge order has been triggered. Clinics are being approached and at least one early pregnancy has been reported following use of Felix.

The next milestones will be more commercially demanding: how quickly clinics adopt the system, whether cartridge consumption becomes recurring, and whether volumes build in line with the contracted schedule.

Vietnam is described by Memphasys as a growing assisted reproductive technology market, supported by increased healthcare investment, rising fertility-service demand and expanding fertility infrastructure in Hanoi and Ho Chi Minh City.

That gives Felix an addressable market, but the size of the opportunity for Memphasys will ultimately depend on execution rather than demographics alone.

For investors, the Vietnam rollout is therefore entering a more informative phase. The regulatory gate has opened. What matters now is how much product moves through it.